Go Pro

Eikon Therapeutics (EIKN) Institutional Ownership

$9.01 -0.49 (-5.11%)
As of 11:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Institutional Ownership Changes (13F Filings) for Eikon Therapeutics (NASDAQ:EIKN)

Number of
Institutional Buyers
(last 12 months)
9
Total
Institutional Inflows
(last 12 months)
$19.21M
Number of
Institutional Sellers
(last 12 months)
1
Total
Institutional Outflows
(last 12 months)
$633.69K
Get EIKN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Eikon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

EIKN Institutional Buying and Selling by Quarter

Eikon Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/9/2026 The Manufacturers Life Insurance Company35,357$461K0.0%N/A0.065%
9/9/2026 Integrated Wealth Concepts LLC10,900$142K0.0%N/A0.020%
9/2/2026 Citadel Advisors LLC13,023$170K0.0%N/A0.024%
8/21/2026 Comprehensive Financial Management LLC116,276$1.52M0.0%N/A0.215%
8/17/2026 Bank of America Corp DE37,575$490K0.0%-56.4%0.069%
8/14/2026 Parkman Healthcare Partners LLC256,053$3.34M0.3%N/A0.473%
8/14/2026 Legal & General Group Plc2,118$28K0.0%N/A0.004%
8/14/2026 The Manufacturers Life Insurance Company35,357$461K0.0%+23.5%0.065%
8/7/2026 BlackRock Inc.4,281,425$55.87M0.0%+29.0%7.908%
8/7/2026 Deutsche Bank AG21,522$281K0.0%N/A0.040%
8/6/2026 Bank of New York Mellon Corp47,788$624K0.0%N/A0.088%


EIKN Institutional Ownership - Frequently Asked Questions

During the previous two years, 10 institutional investors and hedge funds held shares of Eikon Therapeutics. The most heavily invested institutionals were BlackRock Inc. ($55.87M), Parkman Healthcare Partners LLC ($3.34M), Comprehensive Financial Management LLC ($1.52M), Bank of New York Mellon Corp ($624K), Bank of America Corp DE ($490K), The Manufacturers Life Insurance Company ($461K), and Deutsche Bank AG ($281K).Learn more on Eikon Therapeutics' institutional investors.

Of the 9 institutional investors that purchased Eikon Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BlackRock Inc. ($962.05K), Parkman Healthcare Partners LLC ($256.05K), Comprehensive Financial Management LLC ($116.28K), Bank of New York Mellon Corp ($47.79K), The Manufacturers Life Insurance Company ($42.09K), Deutsche Bank AG ($21.52K), and Citadel Advisors LLC ($13.02K).

Institutional investors have bought a total of 1,471,817 shares in the last 24 months. This purchase volume represents approximately $19.21M in transactions.

The following institutional investors have sold Eikon Therapeutics stock in the last 24 months: Bank of America Corp DE ($48.56K).

Institutional investors have sold a total of 48,559 shares in the last 24 months. This volume of shares sold represents approximately $633.69K in transactions.



Institutional ownership data for NASDAQ:EIKN is compiled from quarterly 13F filings submitted to the U.S. Securities and Exchange Commission (SEC), with the most recent received on 9/9/2026. New 13F filings are added each quarter as they're published.
From Our Partners